Safety And Efficacy of Low Dose Oral Anticoagulants And Aspirin Therapy

Safety And Efficacy of Low Dose Oral Anticoagulants And Aspirin Therapy Throughout Pregnancy In Patients With Mechanical Heart Valves Prosthesis

A prospective, randomized, longitudinal, open label, parallel group clinical trial was designed to compare the proportions of failure to reach INR target 2.5-3.5 with either: small dose warfarin (<5 mg/day) or phenindione (<100 mg/day), in high-risk pregnant and non-pregnant patients with bileaflet mechanical heart valve prosthesis.

Study Overview

• Status: Completed
• Conditions: Anticoagulation in Pregnancy
• Intervention / Treatment: Drug: Warfarin; Drug: phenindione

Detailed Description

The patients were chosen from a main population of 3000 females in the child bearing period (18-40 years), with a bileaflet mechanical mitral (+ aortic) valve prosthesis, on regular follow-up at the outpatient clinic of Ain Shams University Hospitals. Patients were primarily screened for their wiliness to participate in the study by expressing their clear wish to become pregnant (Subpopulation A: 310 patients) or otherwise making a clear decision of not becoming pregnant by following a regular contraceptive measure (Subpopulation B: 660 patients).

Study groups A (pregnant) and B (non-pregnant) were then created by assessing the respective subpopulations for the following eligibility criteria (a) regular menstrual cycles and no history of congenital malformation, repeated abortions or still birth; (b) patient in NYHA class I or II c) regular INR records for the last 3 months, with the target INR being achieved with warfarin not exceeding 10 mg/day; d) patient accepting to participate in the study and; (d) getting pregnant for Group A patients, of course Patients were excluded from either groups if they refuse to participate in the study or to sign the informed consent. Pregnant patients were excluded from Group A if reporting their missed menstrual period or positive pregnancy test later than the 6th week of gestation. Patients were excluded from Group B whenever they get pregnant, of course.

A total of 100 patients were intended to be recruited in each group. Out of the 104 patients who met the inclusion criteria of Group A, 4 cases were excluded for reporting pregnancy late at the 9th and 12th week (2 cases; 1.9%) and for refusing to sign the informed consent (2 cases; 1.9%). Out of the 135 patients who met the inclusion criteria of Group B, as much as 35 patients (25.9%) were excluded for refusing to participate in the study.

Randomization and treatment allocation:

In order to become a formal Group A member, patients in subpopulation A were followed up until conception, with clear instructions to report after 3 days of missing a menstrual period and to confirm pregnancy by repeatedly performing pregnancy test every 3 days or until menstruating. Legible patients of both groups had to sign the informed consent before being randomized. We have used a simple 8 elements randomization table, with 6 elements being assigned to warfarin and 2 elements being assigned to phenindione, to create 2 separate randomization lists. Each list was used to randomize the recruited 100 patients of each group to either: low dose warfarin (<5 mg/day) or phenindione (<100 mg/day), in a 3:1 ratio; respectively. In patients assigned to the latter, phenindione replaced warfarin with a starting dose of 50 mg/day (25 mg /day in patients weighing <40 kg.), INR was repeated after 4 days and the dose was adjusted accordingly. All patients targeted an INR between 2.5 and 3.5.

Follow-up:

Patients were followed up till delivery (Group A) or for a whole 9 month's period (Group B). During that time, patients benefited from a monthly cardiac examination, bimonthly checks up for hepatorenal functions and complete blood picture as well as echocardiographic examination. In addition, Group A patients benefited from a monthly obstetrical examination and sonography. All patients were instructed to report any complication immediately and, in Group A, all prescribed drugs were revised by attending obstetrician. Prothrombin time (PT) was done on DADE BEHRING CA 1500 and INR was checked out the day of randomization, after 4 days, 2 weeks and then regularly on a monthly basis. Starting the second trimester (Group A) or the fourth month of follow-up (Group B), 100 mg aspirin was added to all cases. Patients presenting with an INR <20% target were subjected to clinical examination with special emphasis on dietary / bowel habits, recently received medication and INR was repeated 4 days after managing any suspected cause. Patients still failing to reach lower target as well as those initially presenting with an INR below 2 were shifted to the other oral anticoagulant. The starting dose of the latter was calculated on the basis that the anticoagulation effect of 1 mg of warfarin is roughly equivalent to that achieved with 10 mg of phenindione (unpublished experience). In between shifts, the INR gap was bridged with LMWH 1 mg/kg, given twice daily. Patients failing to reach lower INR target with the maximum allowed daily dose of both oral anticoagulants were excluded from the study. Fortnight before delivery, Group A patients were hospitalized and the oral anticoagulant was substituted with continuous infusion of UFH and a planned delivery at 36th week per vagina or by Caesarian section, as indicated.

• Study Type: Interventional
• Enrollment (Actual): 200
• Phase: Phase 3

Contacts and Locations

Study Locations

• Egypt
  • Cairo, Egypt
    • Ain Shams University Hospitals

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 40 years (ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Regular menstrual cycles and no history of congenital malformation, repeated abortions or still birth.
• Patients in NYHA class I or II c) regular INR records for the last 3 months, with the target INR being achieved with warfarin not exceeding 10 mg/day.
• Patient accepting to participate in the study
• Getting pregnant for Group A patients

Exclusion Criteria:

• Patients were excluded from either groups if they refuse to participate in the study or to sign the informed consent.
• Pregnant patients were excluded from Group A if reporting their missed menstrual period or positive pregnancy test later than the 6th week of gestation.
• Patients were excluded from Group B whenever they get pregnant.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: PREVENTION
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: Pregnant; Group of Pregnant patients who will receive either warfarin or phenindione according to the study design	Drug: Warfarin; Low dose warfarin of 5mg or less per day; Drug: phenindione; Phenindione of 100mg or less per day
ACTIVE_COMPARATOR: Non Pregnant; Group Of Non Pregnant patients who will receive either warfarin or phenindione according to the study design	Drug: Warfarin; Low dose warfarin of 5mg or less per day; Drug: phenindione; Phenindione of 100mg or less per day

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
proportions of failure to reach target INR (2.5-3.5) with a maximum daily dose of 5mg warfarin or 100 mg phenindione	Low dose warfarin is recommended for pregnant patients with mechanical heart valves to avoid drug related congenital anomalies. The aim of our study is to question if this low dose can achieve target INR in high risk patients with mechanical heart valves implanted in mitral +/- aortic position.	9 Months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportions of adverse patients (maternal) outcomes	Maternal mortality and anticoagulant related bleeding and thromboembolic events	9 Months
Proportions of adverse fetal outcomes	Proportions of spontaneous abortions, fetal congenital malformations, prematurity, sill birth, neonatal death and total feta wastage.	9 months
INR achieved with a maximum dose of 5mg warfarin or 100 mg phenindione		9 months
Daily dose of oral anticoagulant in pregnant and non pregnant patients		9 Months

Collaborators and Investigators

• Sponsor: Yasser Elnahas
• Investigators: Study Director: Ahmed A Hassouna, M.D, Ain Shams University, Cairo Egypr; Principal Investigator: Yasser M Elnahas, M.D., ain shams University; Principal Investigator: Ahmed M Toema, M.SC., ain shams University; Principal Investigator: ayman Ammar, M.D, ain shams University

Publications and helpful links

General Publications

• Hassouna A, Allam H. Oral anticoagulation therapy during pregnancy in patients with mechanical mitral valves: a prospective study. Cardiovasc Surg. 2001 Oct;9(5):478-81. doi: 10.1016/s0967-2109(01)00020-5.

Study record dates

Study Major Dates

• Study Start: February 1, 2010
• Primary Completion (ACTUAL): June 1, 2012
• Study Completion (ACTUAL): August 1, 2012

Study Registration Dates

• First Submitted: December 25, 2012
• First Submitted That Met QC Criteria: December 25, 2012
• First Posted (ESTIMATE): January 1, 2013

Study Record Updates

• Last Update Posted (ESTIMATE): January 28, 2013
• Last Update Submitted That Met QC Criteria: January 25, 2013
• Last Verified: January 1, 2013

More Information

Terms related to this study

• Keywords: pregnancy; warfarin; mechanical heart valve; phenindione
• Additional Relevant MeSH Terms: Anticoagulants; Warfarin; Phenindione
• Other Study ID Numbers: AINSHAMS2012